Table of Contents
ISRN Hematology
Volume 2011, Article ID 108397, 6 pages
http://dx.doi.org/10.5402/2011/108397
Review Article

Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents

Department of Hematology, Uppsala University Hospital, 751 85 Uppsala, Sweden

Received 5 June 2011; Accepted 25 July 2011

Academic Editors: L. Catalano and H.-M. Tsai

Copyright © 2011 Torbjörn Karlsson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

During the past decade, intravenous iron supplementation to ESA (erythropoiesis-stimulating agent) therapy has emerged as an option to augment hemoglobin response in anemic cancer patients. In this paper, the results of seven published randomized clinical trials assessing the role of iron supplementation to ESA therapy in the hematology/oncology setting will be discussed. The pathogenetic mechanisms behind functional iron deficiency, a major reason for ESA hyporesponsiveness in cancer, will also be described.